Navigation Links
ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
Date:11/8/2010

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced the appointment of Benson Tsang as a member of the Company's Board of Directors and Audit Committee, effective November 8, 2010. Kevin Penghui Chen, the Chief Financial Officer and Chief Operating Officer of ShangPharma, will resign as a member of the Audit Committee, but will remain as a member of the Board.

Benson Tsang has been the Chief Financial Officer and financial and principal accounting officer of ATA Inc. since March 2010.  Mr. Tsang has more than 21 years of experience in accounting, financial management, and the capital markets.  He has held senior financial and management positions in multinational corporations and international accounting firms, and has financial and accounting experience with companies listed on the New York Stock Exchange, The Stock Exchange of Hong Kong, and the Singapore Exchange. Mr. Tsang served as the Chief Financial Officer of WuXi Pharmatech (Cayman) Inc. from July 2006 to February 2009. Prior to that, Mr. Tsang held senior financial and management positions in private and public companies, including PCCW Ltd. and Global Tech Holdings Ltd. He worked at PricewaterhouseCoopers and Deloitte Touche Tohmatsu from 1988 to 1996, and between March 2009 and March 2010, Mr. Tsang provided consulting services through his own firm, the Benita Consulting Company.

Mr. Tsang is a member of the Canadian Institute of Chartered Accountants and the Hong Kong Institute of Certified Public Accountants. He received a Bachelor of Commerce degree and an MBA degree from McMaster University in Canada.

Michael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented, "We are pleased to have Mr. Tsang join our Company as a member of the Board and Audit Committee.  His tremendous experience at publicly-listed companies in both the U.S. and Hong Kong, and knowledge accumulated at two big-four audit firms make him a valuable addition to our team. In particular, he will be a great asset in helping our company fulfill our legal and fiduciary obligations in terms of accounting, auditing, financial reporting, internal control and legal compliance."

ABOUT SHANGPHARMA CORPORATIONShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. For further information, please contact:ShangPharma CorporationLan Xie, VP of Finance and OperationsE-mail: IR@shangpharma.comChristensenIn New YorkKimberly Minarovich, +917-533-3268kminarovich@christensenir.comorIn Hong KongTip Fleming, +852-9212-0684 tfleming@christensenir.com
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
2. China BCT Announces Conference Call to Discuss Third Quarter 2010 Results
3. United American Healthcare Corporation Announces Senior Management Appointments and Relocation to Chicago
4. Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
5. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
7. SPO Announces Completion of Rebranding Program
8. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
9. BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year
10. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
11. Telik Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):